Alberto Gil-Jimenez

7PUBLICATIONS
53CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 17, 2026
Pre-existing immunity and hrHPV status determine immunotherapy response in advanced penile cancer: biomarkers and overall survival in the PERICLES trial.

|Jun 09, 2025
Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study.

Chantal F Stockem, Alberto Gil-Jimenez, Hamza Ali

|Jul 24, 2024
Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer Microenvironment.

Maksim A Chelushkin, Jeroen van Dorp, Sandra van Wilpe

|Mar 22, 2024
Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors.

Alberto Gil-Jimenez, Nick van Dijk, Joris L Vos

|Feb 14, 2024
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.

Maud Rijnders, J Alberto Nakauma-González, Debbie G J Robbrecht

|Jul 24, 2023
Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial.

Hielke M de Vries, Tynisha S Rafael, Alberto Gil-Jimenez

Pageof 2

Frequent Collaborators

7 joint publications

Michiel S van der Heijden

6 joint publications

Erik Hooijberg

5 joint publications

Lodewyk F A Wessels

4 joint publications

Dennis Peters